These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 34732623)
1. [Treatment of secondary engraftment failure with granulocyte colony-stimulating factor and eltrombopag after allogeneic peripheral blood stem cell transplantation in adult T-cell leukemia/lymphoma]. Kiyohara K; Sugawara N; Maeta T; Miyajima S; Takano M; Nishiya M; Nishiya M; Sasaki R; Okano Y; Kamihara S; Kowata S; Oyake T; Ito S Rinsho Ketsueki; 2021; 62(10):1499-1504. PubMed ID: 34732623 [TBL] [Abstract][Full Text] [Related]
2. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia. Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100 [TBL] [Abstract][Full Text] [Related]
3. Comparison of outcome of allogeneic bone marrow transplantation with and without granulocyte colony-stimulating factor (lenograstim) donor-marrow priming in patients with chronic myelogenous leukemia. Ji SQ; Chen HR; Wang HX; Yan HM; Pan SP; Xun CQ Biol Blood Marrow Transplant; 2002; 8(5):261-7. PubMed ID: 12064363 [TBL] [Abstract][Full Text] [Related]
4. [A pilot study of G-CSF mobilized allogeneic bone marrow cells plus peripheral blood stem cells transplantation for malignant hematological diseases]. Chen Y; Huang X; Xu L; Liu D; Zhang Y; Ren H; Guo N; Lu D Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(19):1306-9. PubMed ID: 12509932 [TBL] [Abstract][Full Text] [Related]
5. [Clinical study on haploid HLA-matched hematopoietic stem cell transplantation for treatment of malignant hematological disease]. Sun AN; Wu DP; Wang Y; Qiu HY; Jin ZM; Miao M; Tang XW; Fu ZZ; Ma X; Han Y; He GS; Chen SN; Xue SL; Zhao Y Ai Zheng; 2006 Aug; 25(8):1019-22. PubMed ID: 16965686 [TBL] [Abstract][Full Text] [Related]
6. Impact of stem cell source on allogeneic stem cell transplantation outcome in hematological malignancies. Stamatović D; Balint B; Tukić L; Elez M; Tarabar O; Todorović M; Ostojić G; Tatomirovic Z; Ljubenov M; Marjanović S; Malesević M Vojnosanit Pregl; 2011 Dec; 68(12):1026-32. PubMed ID: 22352263 [TBL] [Abstract][Full Text] [Related]
7. Treatment of relapse after allogeneic bone marrow transplantation with unmanipulated G-CSF-mobilized peripheral blood stem cell preparation. Siegert W; Beyer J; Kingreen D; Blasczyk R; Baurmann H; Schwella N; Schleicher J; Kirsch A; Huhn D Bone Marrow Transplant; 1998 Sep; 22(6):579-83. PubMed ID: 9758347 [TBL] [Abstract][Full Text] [Related]
8. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies. Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687 [TBL] [Abstract][Full Text] [Related]
9. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Körbling M; Przepiorka D; Huh YO; Engel H; van Besien K; Giralt S; Andersson B; Kleine HD; Seong D; Deisseroth AB Blood; 1995 Mar; 85(6):1659-65. PubMed ID: 7888684 [TBL] [Abstract][Full Text] [Related]
10. T cell-depleted granulocyte colony-stimulating factor (G-CSF) modified allogenic bone marrow transplantation for hematological malignancy improves graft CD34+ cell content but is associated with delayed pancytopenia. Mavroudis DA; Read EJ; Molldrem J; Raptis A; Plante M; Carter CS; Phang S; Dunbar CE; Barrett AJ Bone Marrow Transplant; 1998 Mar; 21(5):431-40. PubMed ID: 9535034 [TBL] [Abstract][Full Text] [Related]
12. Effect of splenectomy on pancytopenia after a peripheral blood stem cell transplantation. Ding J; Bao W; Wang J; Zhao G; Chen J; Song H Cell Transplant; 2011; 20(7):1109-15. PubMed ID: 21092413 [TBL] [Abstract][Full Text] [Related]
13. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124 [TBL] [Abstract][Full Text] [Related]
14. Thiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia. Bacigalupo A; Van Lint MT; Valbonesi M; Lercari G; Carlier P; Lamparelli T; Gualandi F; Occhini D; Bregante S; Valeriani A; Piaggio G; Pitto A; Benvenuto F; Figari O; De Stefano G; Caimo A; Sessarego M Blood; 1996 Jul; 88(1):353-7. PubMed ID: 8704195 [TBL] [Abstract][Full Text] [Related]
15. Enhanced antileukemic activity of allogeneic peripheral blood progenitor cell transplants following donor treatment with the combination of granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) in a murine transplantation model. Hartung G; Zeis M; Glass B; Dreger P; Steinmann J; Schmitz N; Uharek L Bone Marrow Transplant; 2003 Jul; 32(1):49-56. PubMed ID: 12815478 [TBL] [Abstract][Full Text] [Related]
16. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease. Pan L; Teshima T; Hill GR; Bungard D; Brinson YS; Reddy VS; Cooke KR; Ferrara JL Blood; 1999 Jun; 93(12):4071-8. PubMed ID: 10361103 [TBL] [Abstract][Full Text] [Related]
17. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. Carella AM; Cavaliere M; Lerma E; Ferrara R; Tedeschi L; Romanelli A; Vinci M; Pinotti G; Lambelet P; Loni C; Verdiani S; De Stefano F; Valbonesi M; Corsetti MT J Clin Oncol; 2000 Dec; 18(23):3918-24. PubMed ID: 11099321 [TBL] [Abstract][Full Text] [Related]
18. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis. Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938 [TBL] [Abstract][Full Text] [Related]
19. Allogeneic blood cell transplantation without posttransplant colony-stimulating factors in patients with hematopoietic neoplasm: a phase II study. Rosenfeld C; Collins R; Piñeiro L; Agura E; Nemunaitis J J Clin Oncol; 1996 Apr; 14(4):1314-9. PubMed ID: 8648389 [TBL] [Abstract][Full Text] [Related]
20. Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. Morton J; Hutchins C; Durrant S Blood; 2001 Dec; 98(12):3186-91. PubMed ID: 11719353 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]